Pathstone Holdings’s Achieve Life Sciences ACHV Stock Holding History

Pathstone Holdings’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-416,667	Closed	-$1.86M	–	2224
2025 Q4	$1.86M	Sell	416,667 -85,333	-17%	-$372K	0.01%	1062
2025 Q3	$1.58M	Buy	+502,000	New	+$1.38M	0.01%	1163

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Holdings's ACHV Position: Q1 2026 in Review

Pathstone Holdings sold out of Achieve Life Sciences (ACHV) in Q1 2026, closing a stake of 416,667 shares — an estimated $1.86M sold.

Pathstone Holdings first reported a position in ACHV in Q3 2025 and held it in 2 quarters. The position peaked at $1.86M in Q4 2025. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

Pathstone Holdings reported no remaining Achieve Life Sciences position as of Q1 2026 after selling out during the quarter.
Pathstone Holdings sold 416,667 Achieve Life Sciences shares in Q1 2026, an estimated $1.86M.
Pathstone Holdings first reported a position in Achieve Life Sciences in Q3 2025 and held it in 2 quarters.
Pathstone Holdings's Achieve Life Sciences position peaked at $1.86M in Q4 2025.
81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.